NBEO Drug list Exam | Questions and Answers |
Verified Solutions | 2026 Edition | Pass
Guaranteed
Save
Terms in this set (297)
Travoprost (Travatan) Prostaglandin Analog
MOA: Increases uveoscleral outflow
Use: glaucoma, IOP lowering
SEs: hypertrichosis, inflammation, orbital
pigmentary changes
CIs: Active inflammation, CME
Dosage: QHS
Pigmentary retinopathy "CPT-I"
- Chlorpromazine
- Promethazine
- Thioridazine
- Indomethacin
Carbonic anhydrase inhibitors Oral
Acetazolamide
Methazolamide
Topical -sopt
Dorzolamide (Trusopt)
Brinzolamide (Azopt)
,Acetazolamide (Diamox) Carbonic anhydrase inhibitor (Oral)
MOA: inhibit CA, reduces active secretion of
aqueous
Use: IOP lowering
SEs: sulfa-based allergies, metallic taste, metabolic
acidosis (diabetic issue), aplastic anemia and bone
marrow suppression
CIs: COPD and pregnancy
Dosage -
1. 2x250 mg tablets for angle closure
2. 500mg slow release tablet but not for AACG
Methazolamide (Neptazane) CAI (Oral)
MOA: inhibit CA to reduce secretion of aqueous
Use: IOP lowering
SEs: allergies, metallic taste, metabolic acidosis
(diabetic issue), aplastic anemia and bone marrow
suppression
CI: COPD and pregnancy
Dorzolamide (Trusopt 2%) CAI (Topical)
MOA: inhibits CA production in ciliary processes
Use: glaucoma, IOP lowering
CIs: sulfa allergies
Dosage: TID
Brinzolamide (Azopt 1%) CAI (Topical)
MOA: inhibits CA production in ciliary processes
Use: glaucoma, IOP lowering
CIs: sulfa allergies
Dosage: TID
, Bimatoprost (Lumigan) Prostaglandin Analog
MOA: Increases uveoscleral outflow
Use: glaucoma, IOP lowering
SEs: hypertrichosis, inflammation, orbital
pigmentary changes
CIs: Active inflammation, CME
Dosage: QHS
Latanoprost (Xalatan) Prostaglandin analog
MOA: Increases uveoscleral outflow
Use: glaucoma, IOP lowering
SEs: hypertrichosis, inflammation, orbital
pigmentary changes
CIs: Active inflammation, CME
Dosage: QHS
Lidocaine Local anesthetic
Sodium channel blocker
MOA: block nerve conduction when applied
locally, amide anesthetic (longer duration)
Use: ophthalmic gel for anesthesia
Proparacaine Local anesthetic - topical
Sodium channel blocker
MOA: block nerve conduction when applied
locally, ester anesthetic (shorter duration)
Use: ophthalmic solution for anesthesia
SEs: corneal melt with excess use
Oxycodone (Oxycontin) Narcotic analgesic Centrally acting
MOA: agonist at mu, kappa, and delta receptors
Use: potent analgesic
SEs: miosis
Verified Solutions | 2026 Edition | Pass
Guaranteed
Save
Terms in this set (297)
Travoprost (Travatan) Prostaglandin Analog
MOA: Increases uveoscleral outflow
Use: glaucoma, IOP lowering
SEs: hypertrichosis, inflammation, orbital
pigmentary changes
CIs: Active inflammation, CME
Dosage: QHS
Pigmentary retinopathy "CPT-I"
- Chlorpromazine
- Promethazine
- Thioridazine
- Indomethacin
Carbonic anhydrase inhibitors Oral
Acetazolamide
Methazolamide
Topical -sopt
Dorzolamide (Trusopt)
Brinzolamide (Azopt)
,Acetazolamide (Diamox) Carbonic anhydrase inhibitor (Oral)
MOA: inhibit CA, reduces active secretion of
aqueous
Use: IOP lowering
SEs: sulfa-based allergies, metallic taste, metabolic
acidosis (diabetic issue), aplastic anemia and bone
marrow suppression
CIs: COPD and pregnancy
Dosage -
1. 2x250 mg tablets for angle closure
2. 500mg slow release tablet but not for AACG
Methazolamide (Neptazane) CAI (Oral)
MOA: inhibit CA to reduce secretion of aqueous
Use: IOP lowering
SEs: allergies, metallic taste, metabolic acidosis
(diabetic issue), aplastic anemia and bone marrow
suppression
CI: COPD and pregnancy
Dorzolamide (Trusopt 2%) CAI (Topical)
MOA: inhibits CA production in ciliary processes
Use: glaucoma, IOP lowering
CIs: sulfa allergies
Dosage: TID
Brinzolamide (Azopt 1%) CAI (Topical)
MOA: inhibits CA production in ciliary processes
Use: glaucoma, IOP lowering
CIs: sulfa allergies
Dosage: TID
, Bimatoprost (Lumigan) Prostaglandin Analog
MOA: Increases uveoscleral outflow
Use: glaucoma, IOP lowering
SEs: hypertrichosis, inflammation, orbital
pigmentary changes
CIs: Active inflammation, CME
Dosage: QHS
Latanoprost (Xalatan) Prostaglandin analog
MOA: Increases uveoscleral outflow
Use: glaucoma, IOP lowering
SEs: hypertrichosis, inflammation, orbital
pigmentary changes
CIs: Active inflammation, CME
Dosage: QHS
Lidocaine Local anesthetic
Sodium channel blocker
MOA: block nerve conduction when applied
locally, amide anesthetic (longer duration)
Use: ophthalmic gel for anesthesia
Proparacaine Local anesthetic - topical
Sodium channel blocker
MOA: block nerve conduction when applied
locally, ester anesthetic (shorter duration)
Use: ophthalmic solution for anesthesia
SEs: corneal melt with excess use
Oxycodone (Oxycontin) Narcotic analgesic Centrally acting
MOA: agonist at mu, kappa, and delta receptors
Use: potent analgesic
SEs: miosis
